Himalaya Nutravedics India Ltd IPO
Pharmaceuticals
Price Band
₹100 – ₹106
Lot Size
1200
Minimum Bid Quantity
2400
Minimum Investment
₹254400
Issue Size
₹26.5Cr
Opens
2026-09-22
Closes
2026-09-24
Listing
29-09-2026
Subscription Status
Qualified Institutional Buyers
1 x
Non-Institutional Investor
2.83 x
Retail Individual Investor
2.54 x
Total
2.21 x
IPO Details
Issue Type
EQUITY
Face Value
₹10
Tick Size
1
ISIN
INE1OTR01013
Pre-Apply Available
No
Daily Bidding Time
10:00:00 - 17:00:00
About the Company
Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. Its product portfolio includes classical Ayurvedic formulations based on recognised Ayurvedic texts, proprietary Ayurvedic formulations and nutraceutical supplements. The products are available in dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. Its nutraceutical products include formulations using vitamins, minerals, herbal extracts, amino acids and other permitted ingredients. The company operates through both its own-brand and third-party manufacturing businesses. It commenced manufacturing operations in September 2022 from its facility in Cherlapally, Hyderabad, Telangana. The company has a stockist-driven distribution network across multiple states in India and an on-ground sales and marketing team of approximately 56 personnel, including regional managers and medical representatives. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Funding capital expenditure requirements — Rs 13.75 crore Investment in branding, digital marketing, and sales expansion — Rs 7.50 crore General corporate purposes.
Pros
- • The company claims to operate an integrated manufacturing facility capable of producing medicated oils, soft gelatin capsules, hard gelatin capsules, tablets and liquid orals. This allows it to manufacture products across multiple dosage forms for its Ayurvedic and nutraceutical businesses.
- • Since commencing manufacturing operations in September 2022, the company has established a presence across multiple states in India. It has built a stockist-driven distribution network supported by an on-ground sales and marketing team.
- • The company offers classical Ayurvedic formulations, proprietary Ayurvedic formulations, and nutraceutical supplements across areas such as gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, infertility, and general wellness.
Cons
- • The company’s two trademark applications are currently being contested. The applications for the “Himalaya Nutravedics” wordmark and “Himalaya Nutravedics – Supplements That Heal” mark were filed in October 2022 and are currently opposed before the Registrar of Trademarks. Any adverse outcome could require the company to modify, replace, or discontinue the use of the opposed trademarks, potentially affecting the recognition and goodwill associated with its products.
- • The company’s revenue is heavily dependent on the sale of Ayurvedic products, which accounted for Rs 40.73 crore (94.57%) of revenue from operations in FY26, Rs 19.33 crore (92.09%) in FY25, and Rs 11.43 crore (79.27%) in FY24. Any fall in demand for Ayurvedic products due to competition, regulatory action, pricing pressures, or the availability of alternative products could adversely affect the company’s business and financial performance.
- • The company is dependent on a limited number of customers, with its top 10 customers contributing Rs 34.99 crore (81.24%) of revenue from operations in FY26, compared with Rs 18.26 crore (86.97%) in FY25 and Rs 12.14 crore (84.19%) in FY24. Any loss of key customers, cancellation or reduction of orders, or delays in orders could adversely affect the company’s business and financial performance, particularly as it does not maintain long-term contractual arrangements with its customers.
Get real-time IPO alerts on WhatsApp
Opening reminders • Subscription updates • GMP alerts • Allotment results
Start WhatsApp Alerts